NCT06374420

Brief Summary

The aim of this work is to estimate the frequency of small airway disease and/or the bronchial hyperreactivity in follow up of postacute covid survivors.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2023

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2024

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

April 16, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 18, 2024

Completed
Last Updated

April 19, 2024

Status Verified

April 1, 2024

Enrollment Period

2 years

First QC Date

April 16, 2024

Last Update Submit

April 18, 2024

Conditions

COVID-19

Outcome Measures

Primary Outcomes (2)

  • investigating pulmonary sequelae of covid-19.

    The selected post covid patients on the day of their clinic visit (one to three months after being diagnosed covid 19

    3moth

  • investigating pulmonary sequelae of covid-19.

    The selected post covid patients on the day of their clinic visit (6 months after being diagnosed covid 19

    6 month

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adults with confirmed covid 19 who remaining symptomatic after 30 days from the diagnosis.

You may qualify if:

  • Ambulatory adult patients confirmed diagnosis of covid -19 either on typical CT chest basis or PCR and passed period of acute illness (28 days from start of symptoms) but still with clinical symptoms.

You may not qualify if:

  • Hospitalized or requiring intensive care unit. Known patients with chronic lung diseases Uncontrolled comorbidities

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mansoura University

Al Mansurah, Dakhlia, 050, Egypt

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

April 16, 2024

First Posted

April 18, 2024

Study Start

September 1, 2021

Primary Completion

September 1, 2023

Study Completion

April 1, 2024

Last Updated

April 19, 2024

Record last verified: 2024-04

Locations

EG(1)